Scientist | RNA Biology & Neuromuscular Gene Therapy

The role

This scientist will lead research on AAV-tRNA therapies to restore or enhance tRNA function in neuromuscular conditions. The role involves optimizing gene delivery, executing in vivo and in vitro efficacy studies, and conducting toxicology assessments.

What you will do

• Develop and test novel constructs aimed at restoring or enhancing tRNA function in neuromuscular conditions.
• Evaluate different AAV capsids, administration routes, and dosage regimens.
• Execute and supervise experimental workflows in rodent models of neuromuscular disorders.
• Design and execute animal studies to evaluate the toxicology profile of therapeutic constructs.
• Contribute to next-generation RNA-based therapeutics by exploring suppressor tRNAs.
• Interpret complex datasets and communicate findings to internal teams, external collaborators, and potential investors.
• Work closely with colleagues in vector manufacturing, quality/regulatory planning, and intellectual property.
• Participate in cross-functional discussions to align scientific developments with corporate milestones.

Required qualifications

• PhD in Molecular Biology, Genetics, Neuroscience, or related discipline
• Strong background in RNA biology, gene therapy, and/or neuromuscular disease research
• Based in the Netherlands and able to work on site in Nijmegen full time
• Track record of independent research, evidenced by publications, conference presentations, or patents relevant to RNA therapeutics or gene therapy
• Demonstrated proficiency in rodent model handling (Article 9 or FELASA certification, dosing, behavioral assessments, tissue dissection)
• Proficiency in molecular analyses (qPCR, RNA FISH, Northern blotting, histopathology)
• Entrepreneurial mindset with the adaptability to thrive in a fast-paced, start-up environment
• Exceptional communication and collaboration skills

Nice to have

• Experience working with AAV vectors (design, in vivo administration, analytics)

About the company

XtRNA Bio is a spin-out from Radboud University, co-founded by Professor Erik Storkebaum and NLC Health Ventures. The company aims to deliver disease-modifying treatments by pioneering tRNA-based therapies.